Effect of nebolized Tubramycin in treatment of ventilator associated pneumonia

Comparison the effects of Meropenem,intravenous Colistin plus nebolized Colistin and Meropenem,intravenous Colistin plus nebolized Tubramycin on treating patients with ventilator associated pneumonia (VAP) due to multidrug_resistance Acintobacter

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150824023743N3

Enrollment

Registered

2019-12-31

Start date

2017-04-21

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator associated pneumonis. Other infectious disease

Interventions

Intervention 1: Intervention group: This group recieved Meropenem(Dana company) 2g every 8 hour , injectable Colistin(Exir company) 4/5 million IU every 12 hours , plus nebolized Tubramycin 300 mg ev

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Mechanical ventilator more than 48 hours Multidrug_resistance Acintobacter in tracheal cultures Satisfaction with the first class family

Exclusion criteria

Exclusion criteria: Allergy to colistin Other infections

Design outcomes

Primary

Measure	Time frame
Clinical pulmunary infection score. Timepoint: 1 , 3 , 5 , 7 and 14 after intervention. Method of measurement: Calculate the clinical pulmunary infection score table.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShoeleh Yaghoubi

Esfahan University of Medical Sciences

Sholeyaqubi@gmail.com+98 31 0048 3668

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026